Study of a Novel Indibulin Dosing Schedule for the Treatment of Metastatic Breast Cancer

NCT01113970 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Breast Cancer

Interventions

DRUG: Indibulin

Sponsor

Alaunos Therapeutics

Collaborators

[object Object]